2. Search Result
Search Result
Results for "

Patch-clamp

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144287
    Glucokinase activator 3

    		Glucokinase Sodium Channel Metabolic Disease
    Glucokinase activator 3 is an orally active Glucokinase (GK) activator with an AC50 of 38 nM. Glucokinase activator 3 inhibits hERG channel and sodium channel in patch clamp assays. Glucokinase activator 3 exhibits high efficacy in reducing blood glucose in diet-induced obese (DIO) mice. Glucokinase activator 3 has the potential for the research of type 2 diabetes .
    Glucokinase activator 3
  • HY-137016A
    8-Pcpt-cGMP sodium
    1 Publications Verification

    		 HCN Channel Neurological Disease
    8-Pcpt-cGMP sodium is the sodium salt form of 8-Pcpt-cGMP (HY-137016). 8-Pcpt-cGMP sodium is an agonist for cyclic nucleotide-gated (CNG) channel with an EC50 of 0.5 μM. 8-Pcpt-cGMP sodium exhibits good membrane permeability. 8-Pcpt-cGMP sodium can be used in studies about the function of CNG channels in visual signal transduction and olfactory transduction .
    8-Pcpt-cGMP sodium
  • HY-153508
    ANO1-IN-4

    		Chloride Channel Others
    ANO1-IN-4 (Compound 10bm) is a reversible inhibitor for calcium-activated chloride channel transmembrane protein 16A (TMEM16A, also known as ANO1) with an IC50 of 0.030 µM. ANO1-IN-4 exhibits good metabolic stability in rat liver microsomes. ANO1-IN-4 inhibits spontaneous contraction in mouse isolated ileum .
    ANO1-IN-4
  • HY-18600A
    Azimilide dihydrochloride
    2 Publications Verification

    NE-10064 dihydrochloride

    		 Potassium Channel Calcium Channel Sodium Channel Cardiovascular Disease
    Azimilide (NE-10064) dihydrochloride is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide dihydrochloride is a dual blocker of IKs (IC50 = 2.6 μM (2mM [K⁺]ₑ)) and IKr (IC50 = 1 μM (4 mM [K⁺])). Azimilide dihydrochloride blocked HERG channel at 0.1 and 1 Hz with IC50s of 1.4 μM and 5.2 μM respectively. Azimilide dihydrochloride also inhibits L-type calcium current (ICa) (IC50 = 17.8 μM) and sodium current (INa) (IC50 = 19 μM). Azimilide dihydrochloride can be used for the study of atrial fibrillation and ventricular fibrillation .
    Azimilide dihydrochloride
  • HY-18600
    Azimilide
    2 Publications Verification

    NE-10064

    		 Potassium Channel Calcium Channel Sodium Channel Cardiovascular Disease
    Azimilide (NE-10064) is a class III antiarrhythmic agent, which works by blocking potassium channels in the heart. Azimilide is a dual blocker of IKs (IC50 = 2.6 μM (2mM [K⁺]ₑ)) and IKr (IC50 = 1 μM (4 mM [K⁺])). Azimilide blocked HERG channel at 0.1 and 1 Hz with IC50s of 1.4 μM and 5.2 μM respectively. Azimilide also inhibits L-type calcium current (ICa) (IC50 = 17.8 μM) and sodium current (INa) (IC50 = 19 μM). Azimilide can be used for the study of atrial fibrillation and ventricular fibrillation .
    Azimilide
  • HY-120059
    NS4591

    		Potassium Channel Neurological Disease
    NS4591 is a modulator of calcium-activated potassium channels with activity that enhances small (SK) and intermediate (IK) conductivity. NS4591 doubled IK-mediated currents in whole-cell patch-clamp experiments at a concentration of 45 +/- 6 nM, and doubled SK3-mediated currents at a concentration of 530 +/- 100 nM. NS4591 inhibits the number of action potentials generated by suprathreshold depolarizing pulses in acutely isolated bladder primary afferent neurons. NS4591 also reduced carbakol-induced detrusor ring contraction in the rat bladder, demonstrating sensitivity to apamin .
    NS4591
  • HY-121183
    Aprikalim

    RP 52891

    		 Potassium Channel Cardiovascular Disease
    Aprikalim (RP 52891), a potassium channel opener (KCO), activates ATP-sensitive K+ (KATP) channels in guinea pig ventricular myocytes. Using patch-clamp techniques, it was found that aprikalim enhances KATP channel activity more effectively in Mg-NDP solution compared to standard solutions. In Mg-NDP solution, aprikalim reduced the sensitivity of KATP channels to ATP, increasing the concentration of ATP required to inhibit channel activity by half (K1) from 56 μM to 180 μM. However, this effect diminished over time. Aprikalim's ability to activate KATP channels in Mg-NDP solution suggests potential therapeutic implications in modulating cardiac excitability and may relate to changes in channel protein enzymatic activity under experimental conditions .
    Aprikalim
  • HY-178058
    VU6080824

    		Potassium Channel Others
    VU6080824 (Compound 5s), a derivative of ML-133 (HY-100230), is an inward-rectifier potassium channel (Kir2.1) inhibitor with an IC50 of 0.35  μM. VU6080824 has superior thallium flux and manual patch clamp (MPC) functional potency .
    VU6080824
  • HY-137016
    8-Pcpt-cGMP

    		HCN Channel Neurological Disease
    8-Pcpt-cGMP is an agonist for cyclic nucleotide-gated (CNG) channel with an EC50 of 0.5 μM. 8-Pcpt-cGMP exhibits good membrane permeability. 8-Pcpt-cGMP can be used in studies about the function of CNG channels in visual signal transduction and olfactory transduction .
    8-Pcpt-cGMP
  • HY-137639
    Sp-8-Br-cGMPS

    		HCN Channel Neurological Disease
    Sp-8-Br-cGMPS is an analog of cGMP. Sp-8-Br-cGMPS is an agonist for cGMP-gated cation channels (CNG channels), with an EC50 of 106.5 μM. Sp-8-Br-cGMPS induces the currents, without the ability to stabilize the channel open state as a full agonist .
    Sp-8-Br-cGMPS
  • HY-114540
    CP-339818

    		Potassium Channel HCN Channel Neurological Disease
    CP-339818 is a non-peptide Kv1.3 channel (IC50 = 200 nM) and Kv1.4 channel blocker. CP 339818 inhibits HCN channel with IC50s of 18.9 μM and 43.4 μM against HCN1 and HCN4 (high Cl -). CP-339818 has significantly weaker blocking effects on Kv1.1, Kv1.2, Kv1.5, Kv1.6, Kv3.1-4, and Kv4.2 channels. CP-339818 selectively blocked Kv1.3, thereby inhibiting the activation process of human T cells. CP-339818 can be used to study the physiological functions of HCN and Kv channels .
    CP-339818
  • HY-122560A
    VU0134992 hydrochloride
    3 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    VU0134992 hydrochloride is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 hydrochloride is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
    VU0134992 hydrochloride
  • HY-14149A
    Cisapride monohydrate

    R 51619 monohydrate; (±)-Cisaprid monohydrate

    		 5-HT Receptor Neurological Disease Metabolic Disease
    Cisapride monohydrate is an orally and potent 5-HT4 receptor agonist and hERG inhibitor. Cisapride monohydrate is an prokinetic agent which facilitates or restores motility throughout the length of the gastrointestinal tract. Cisapride monohydrate stimulates gastrointestinal motor activity through an indirect mechanism involving the release of acetylcholine mediated by postganglionic nerve endings in the myenteric plexus of the gut .
    Cisapride monohydrate
  • HY-14149
    Cisapride
    1 Publications Verification

    R 51619; (±)-Cisaprid

    		 5-HT Receptor Potassium Channel Neurological Disease
    Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is a hERG blocker with an IC50 value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .
    Cisapride
  • HY-14149R
    Cisapride (Standard)

    R 51619 (Standard); (±)-Cisaprid (Standard)

    		 Reference Standards 5-HT Receptor Potassium Channel Neurological Disease
    Cisapride (Standard) is the analytical standard of Cisapride. This product is intended for research and analytical applications. Cisapride (R 51619) is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. Cisapride is a hERG blocker with an IC50 value of 9.4 nM. Cisapride is a gastroprokinetic agent that stimulates gastrointestinal motor activity .
    Cisapride (Standard)
  • HY-122560
    VU0134992

    		Potassium Channel Cardiovascular Disease
    VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
    VU0134992

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: